This is a transformative pipeline event that de-risks the nHCM opportunity and supports peak sales estimates well above current consensus. Watch for FDA acceptance of the sNDA and potential accelerated review given the unmet need. The safety signal (LVEF <50%) is manageable but will require monitoring in the label.
Price Chart
Executive Summary
Cytokinetics announced positive Phase 3 results from ACACIA-HCM, the first-ever successful trial in non-obstructive HCM. The trial met both dual primary endpoints with statistical significance, and the company plans to submit a supplemental New Drug Application to the FDA in Q4 2026. This expands the potential label for aficamten (MYQORZO) from obstructive to the full spectrum of symptomatic HCM, representing a major pipeline catalyst.
Key Facts
- ACACIA-HCM met both dual primary endpoints: KCCQ-CSS (p=0.021) and pVO2 (p=0.003) at Week 36 vs placebo
- Supplemental NDA for aficamten in non-obstructive HCM to be submitted to FDA in Q4 2026
- Results presented at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine
- Aficamten is already approved as MYQORZO for obstructive HCM in the U.S., China, EU, and UK
- LVEF <50% occurred in 10.5% of aficamten patients vs 0.8% on placebo; serious adverse events 20.2% vs 14.7%
Financial Impact
Potential label expansion to cover ~50% of HCM patients (non-obstructive population), doubling the addressable market for aficamten
Risk Factors
- FDA may require additional data or raise concerns about the LVEF <50% safety signal (10.5% vs 0.8%)
- Competition from other cardiac myosin inhibitors in development for nHCM
- Commercial execution risk in expanding from oHCM to nHCM market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-372456 |
| Document: 0001193125-26-372456-index.html | 0001193125-26-372456 |
| Document: 0001193125-26-372456.txt | 0001193125-26-372456 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access